LeMaitre Vascular (LMAT) Resumen de Acciones
LeMaitre Vascular, Inc. desarrolla, fabrica y comercializa dispositivos e implantes médicos utilizados en el campo de la cirugía vascular en América, Europa, Oriente Medio, África y Asia-Pacífico. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 2/6 |
| Crecimiento futuro | 1/6 |
| Rendimiento pasado | 5/6 |
| Salud financiera | 5/6 |
| Dividendos | 4/6 |
LMAT Community Fair Values
Create NarrativeSee what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de LeMaitre Vascular, Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$91.92 |
| Máximo en las últimas 52 semanas | US$118.01 |
| Mínimo de 52 semanas | US$79.01 |
| Beta | 0.52 |
| Cambio en 1 mes | -5.54% |
| Variación en 3 meses | -18.10% |
| Cambio de 1 año | 11.96% |
| Variación en 3 años | 37.48% |
| Variación en 5 años | 46.16% |
| Variación desde la OPV | 1,382.58% |
Noticias y actualizaciones recientes
Actualización de narrativa • Jun 11
LMAT: Future Cash Returns May Support Raised 2026 Guidance And Premium P/E
Analysts have lifted their price target on LeMaitre Vascular by $25, citing updated assumptions around the discount rate, long term revenue growth, profit margins, and future P/E as key drivers of their revised view. Analyst Commentary Recent research updates on LeMaitre Vascular show a cluster of price target increases and a neutral initiation, providing a mix of both optimistic and cautious viewpoints on the stock.Actualización de narrativa • May 28
LMAT: Future Cash Returns May Support Raised Earnings Guidance And Premium P/E
LeMaitre Vascular's analyst price target has been updated to $118.75 from $111.22, as analysts factor in revised fair value assumptions, a slightly lower discount rate, modestly adjusted revenue growth expectations, and a higher projected P/E multiple supported by recent research updates from multiple firms. Analyst Commentary Recent research updates show a cluster of higher price targets for LeMaitre Vascular, alongside at least one more neutral stance, giving you a mix of optimistic and cautious views to weigh.Actualización de narrativa • Apr 27
LMAT: Future Cash Returns And Operating Leverage May Sustain Current Premium
Narrative Update on LeMaitre Vascular The updated analyst price target for LeMaitre Vascular moves to $117 from $108. This reflects analysts' focus on recent double digit organic growth, margin expansion, strong cash flow, and better than expected Q4 results with operating leverage.Recent updates
Actualización de narrativa • Jun 11
LMAT: Future Cash Returns May Support Raised 2026 Guidance And Premium P/E
Analysts have lifted their price target on LeMaitre Vascular by $25, citing updated assumptions around the discount rate, long term revenue growth, profit margins, and future P/E as key drivers of their revised view. Analyst Commentary Recent research updates on LeMaitre Vascular show a cluster of price target increases and a neutral initiation, providing a mix of both optimistic and cautious viewpoints on the stock.Actualización de narrativa • May 28
LMAT: Future Cash Returns May Support Raised Earnings Guidance And Premium P/E
LeMaitre Vascular's analyst price target has been updated to $118.75 from $111.22, as analysts factor in revised fair value assumptions, a slightly lower discount rate, modestly adjusted revenue growth expectations, and a higher projected P/E multiple supported by recent research updates from multiple firms. Analyst Commentary Recent research updates show a cluster of higher price targets for LeMaitre Vascular, alongside at least one more neutral stance, giving you a mix of optimistic and cautious views to weigh.Actualización de narrativa • Apr 27
LMAT: Future Cash Returns And Operating Leverage May Sustain Current Premium
Narrative Update on LeMaitre Vascular The updated analyst price target for LeMaitre Vascular moves to $117 from $108. This reflects analysts' focus on recent double digit organic growth, margin expansion, strong cash flow, and better than expected Q4 results with operating leverage.Actualización de narrativa • Apr 13
LMAT: Future Margin Discipline And Cash Returns May Support Current Premium
Narrative Update on LeMaitre Vascular The updated analyst price target for LeMaitre Vascular now reflects a modestly higher fair value estimate of about $111.22. This is supported by Street research that highlights continued double digit organic sales growth, material margin expansion, strong cash flow and operating leverage in the wake of better than expected Q4 results and guidance.Actualización de narrativa • Mar 29
LMAT: Future Cash Returns And Margin Discipline May Sustain Current Premium
Narrative Update Analysts have raised LeMaitre Vascular's price targets by $10 to $12, now in a $105 to $117 range. They cite double digit organic revenue growth, margin expansion, strong cash flow, better than expected Q4 results, and operating leverage.Actualización de narrativa • Mar 14
LMAT: Future Margin Execution And Capital Returns May Support Current Premium
Narrative Update on LeMaitre Vascular Our analyst fair value estimate for LeMaitre Vascular has been lifted from $109.22 to $111.00, reflecting updated price targets from $95 to $105 and from $108 to $117 as analysts point to double digit organic growth, margin expansion, and operating leverage following better than expected Q4 results and guidance. Analyst Commentary Recent price target increases to $105 and $117 signal that bullish analysts are incorporating stronger fundamentals into their models following the latest Q4 print and guidance.Actualización de narrativa • Feb 28
LMAT: Future Margin Gains And Capital Returns May Sustain Current Premium
Analysts have increased their implied fair value estimate for LeMaitre Vascular by about $4 to roughly $109, citing recent price target increases to $105 and $117 that they attribute to double-digit organic sales growth, margin expansion and operating leverage. Analyst Commentary Bullish Takeaways Bullish analysts point to double digit organic sales growth as a key support for their higher fair value views, seeing current revenue trends as consistent with a premium valuation versus slower growing peers.Seeking Alpha • Feb 27
LeMaitre Vascular: The Compounder Keeps Compounding
Summary LeMaitre Vascular delivered strong Q4 and FY 2025 results, with 16% YoY sales growth and broad-based margin expansion. Artegraft’s international rollout exceeded expectations, with 2025 sales doubling guidance and a projected $10M in 2026. This could drive earnings growth for years to come. LMAT maintains a robust $190M net cash position and recently increased its dividend by 25%. The board has also authorized a $100M share repurchase program. Operating leverage, pricing power, and international expansion are all key drivers in raising my price target to $116-$130 for year-end 2026. I reiterate my Buy rating. Read the full article on Seeking AlphaArtículo de análisis • Feb 06
Here's Why LeMaitre Vascular (NASDAQ:LMAT) Has Caught The Eye Of Investors
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Artículo de análisis • Jan 03
LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Shares May Have Run Too Fast Too Soon
With a price-to-earnings (or "P/E") ratio of 34.1x LeMaitre Vascular, Inc. ( NASDAQ:LMAT ) may be sending very bearish...Artículo de análisis • Oct 26
Investors Met With Slowing Returns on Capital At LeMaitre Vascular (NASDAQ:LMAT)
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Firstly, we'd want to...Artículo de análisis • Aug 30
Here's Why LeMaitre Vascular (NASDAQ:LMAT) Has Caught The Eye Of Investors
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Artículo de análisis • Aug 06
LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Could Be 25% Above Their Intrinsic Value Estimate
Key Insights LeMaitre Vascular's estimated fair value is US$68.59 based on 2 Stage Free Cash Flow to Equity Current...Artículo de análisis • Jul 18
Is LeMaitre Vascular (NASDAQ:LMAT) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Artículo de análisis • Jun 18
Earnings Not Telling The Story For LeMaitre Vascular, Inc. (NASDAQ:LMAT)
LeMaitre Vascular, Inc.'s ( NASDAQ:LMAT ) price-to-earnings (or "P/E") ratio of 40.5x might make it look like a strong...Artículo de análisis • Apr 24
Should You Be Adding LeMaitre Vascular (NASDAQ:LMAT) To Your Watchlist Today?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Artículo de análisis • Apr 12
Does LeMaitre Vascular (NASDAQ:LMAT) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Artículo de análisis • Mar 31
LeMaitre Vascular (NASDAQ:LMAT) Will Want To Turn Around Its Return Trends
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Ideally, a business...Artículo de análisis • Mar 11
LeMaitre Vascular's (NASDAQ:LMAT) Shareholders Will Receive A Bigger Dividend Than Last Year
LeMaitre Vascular, Inc.'s ( NASDAQ:LMAT ) dividend will be increasing from last year's payment of the same period to...Artículo de análisis • Mar 02
Earnings Update: Here's Why Analysts Just Lifted Their LeMaitre Vascular, Inc. (NASDAQ:LMAT) Price Target To US$105
Shareholders might have noticed that LeMaitre Vascular, Inc. ( NASDAQ:LMAT ) filed its yearly result this time last...Artículo de análisis • Feb 04
When Should You Buy LeMaitre Vascular, Inc. (NASDAQ:LMAT)?
While LeMaitre Vascular, Inc. ( NASDAQ:LMAT ) might not have the largest market cap around , it received a lot of...Artículo de análisis • Jan 22
We Ran A Stock Scan For Earnings Growth And LeMaitre Vascular (NASDAQ:LMAT) Passed With Ease
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Seeking Alpha • Jan 15
LeMaitre Vascular: Losing Steam
Summary LeMaitre Vascular, Inc. has seen a 65% stock rise over 12 months but trades at high valuations with decelerating growth projections. Q3 results showed strong performance with 46% profit growth and 15.7% revenue increase, driven by grafts, patches, and carotid shunts. The stock has dipped some 15% recently. Buy the dip? An analysis around LeMaitre Vascular follows in the paragraphs below. Read the full article on Seeking AlphaArtículo de análisis • Jan 09
A Look At The Fair Value Of LeMaitre Vascular, Inc. (NASDAQ:LMAT)
Key Insights LeMaitre Vascular's estimated fair value is US$96.24 based on 2 Stage Free Cash Flow to Equity Current...Artículo de análisis • Dec 22
LeMaitre Vascular (NASDAQ:LMAT) Has More To Do To Multiply In Value Going Forward
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Artículo de análisis • Nov 24
LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) 26% Price Boost Is Out Of Tune With Earnings
LeMaitre Vascular, Inc. ( NASDAQ:LMAT ) shares have had a really impressive month, gaining 26% after a shaky period...Seeking Alpha • Nov 03
LeMaitre Vascular: The Market Is Catching On To This Dividend Growth Story
Summary LeMaitre continues to expand in the peripheral vascular disease market, with recent revenue gains driven by premium pricing and international growth. Its strong dividend growth of 14.3% this year and double-digit CAGR over the past five years are particularly appealing. With a high-margin, low-competition niche and accelerating geographic expansion, LeMaitre remains well-positioned for sustained growth. Read the full article on Seeking AlphaArtículo de análisis • Nov 02
LeMaitre Vascular, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
As you might know, LeMaitre Vascular, Inc. ( NASDAQ:LMAT ) just kicked off its latest quarterly results with some very...Artículo de análisis • Oct 08
Is LeMaitre Vascular, Inc. (NASDAQ:LMAT) Potentially Undervalued?
While LeMaitre Vascular, Inc. ( NASDAQ:LMAT ) might not have the largest market cap around , it saw a double-digit...Artículo de análisis • Sep 17
Investors Met With Slowing Returns on Capital At LeMaitre Vascular (NASDAQ:LMAT)
To find a multi-bagger stock, what are the underlying trends we should look for in a business? In a perfect world, we'd...
Nueva narrativa • Sep 11
Expanding Market Reach And Calculated Acquisitions Set To Fuel Robust Revenue And Earnings Growth
Expansion in North America and new regulatory approvals in Europe and Asia-Pacific indicate potential revenue growth from increased market share and customer reach.Artículo de análisis • Sep 04
LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Price In Tune With Earnings
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 17x, you may...Artículo de análisis • Aug 22
If EPS Growth Is Important To You, LeMaitre Vascular (NASDAQ:LMAT) Presents An Opportunity
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Seeking Alpha • Jul 23
LeMaitre Vascular: A Small Cap With Best-In-Industry Growth
Summary I outline why LeMaitre Vascular is my top choice in the Health Care Equipment industry and one of the best small caps in the sector. LeMaitre has shown incredible revenue and EPS growth since its IPO and also offers a well-supported, fast-growing dividend. Despite a seemingly high valuation, further growth is expected. Read the full article on Seeking AlphaArtículo de análisis • Jul 12
Is LeMaitre Vascular, Inc. (NASDAQ:LMAT) Worth US$85.0 Based On Its Intrinsic Value?
Key Insights LeMaitre Vascular's estimated fair value is US$70.02 based on 2 Stage Free Cash Flow to Equity Current...Artículo de análisis • Jun 18
Is There Now An Opportunity In LeMaitre Vascular, Inc. (NASDAQ:LMAT)?
LeMaitre Vascular, Inc. ( NASDAQ:LMAT ), might not be a large cap stock, but it led the NASDAQGM gainers with a...Artículo de análisis • Jun 05
Return Trends At LeMaitre Vascular (NASDAQ:LMAT) Aren't Appealing
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'll...Artículo de análisis • May 02
LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Popularity With Investors Is Clear
With a price-to-earnings (or "P/E") ratio of 49.8x LeMaitre Vascular, Inc. ( NASDAQ:LMAT ) may be sending very bearish...Artículo de análisis • Apr 04
Is Now The Time To Put LeMaitre Vascular (NASDAQ:LMAT) On Your Watchlist?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Artículo de análisis • Feb 29
Calculating The Fair Value Of LeMaitre Vascular, Inc. (NASDAQ:LMAT)
Key Insights The projected fair value for LeMaitre Vascular is US$68.32 based on 2 Stage Free Cash Flow to Equity...Artículo de análisis • Jan 19
What Does LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Share Price Indicate?
LeMaitre Vascular, Inc. ( NASDAQ:LMAT ), might not be a large cap stock, but it led the NASDAQGM gainers with a...Rentabilidad de los accionistas
| LMAT | US Medical Equipment | Mercado US | |
|---|---|---|---|
| 7D | -3.4% | 0.02% | 0.5% |
| 1Y | 12.0% | -20.4% | 23.5% |
Rentabilidad vs. Industria: LMAT superó a la industria US Medical Equipment, que obtuvo un rendimiento del -20.4% el año pasado.
Rentabilidad vs. Mercado: LMAT obtuvo unos resultados inferiores a los del mercado US, que fueron del 23.5% el año pasado.
Volatilidad de los precios
| LMAT volatility | |
|---|---|
| LMAT Average Weekly Movement | 4.5% |
| Medical Equipment Industry Average Movement | 8.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Precio estable de las acciones: LMAT no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de LMAT (4%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1983 | 651 | George LeMaitre | www.lemaitre.com |
LeMaitre Vascular, Inc. desarrolla, fabrica y comercializa dispositivos e implantes médicos utilizados en el campo de la cirugía vascular en América, Europa, Oriente Medio, África y Asia-Pacífico. La empresa ofrece aloinjertos, que son injertos de tejido humano crioconservado utilizados en la reconstrucción vascular y la reparación y reconstrucción cardiacas; catéteres de embolectomía para eliminar coágulos sanguíneos de las arterias; catéteres de trombectomía para eliminar trombos en el sistema venoso; catéteres de oclusión que ocluyen temporalmente el flujo sanguíneo; y catéteres de perfusión para perfundir la sangre y otros fluidos en la vasculatura, así como servicios de crioconservación de tejido de cadáver humano. Ofrece un conjunto de productos biológicos que comprende el injerto biológico artegraft, una arteria carótida bovina utilizada para el acceso a diálisis; los parches biológicos XenoSure, utilizados para el cierre de vasos tras una intervención quirúrgica; los parches biológicos VascuCel y CardioCel, utilizados en la reparación de vasos, la reparación y reconstrucción cardiaca y las reparaciones neonatales; derivaciones carotídeas que desvían temporalmente la sangre al cerebro; injertos vasculares biosintéticos indicados para derivación de extremidades inferiores y acceso a diálisis; sistema de flebectomía para resección y ablación de varices; injertos vasculares LifeSpan, que son injertos de politetrafluoroetileno expandido; e injertos vasculares utilizados para derivar o sustituir arterias enfermas.
Resumen de fundamentos de LeMaitre Vascular, Inc.
| Estadísticas fundamentales de LMAT | |
|---|---|
| Capitalización bursátil | US$2.10b |
| Beneficios(TTM) | US$62.40m |
| Ingresos (TTM) | US$256.28m |
33.7x
Ratio precio-beneficio (PE)8.2x
Ratio precio-ventas (PS)¿Está LMAT sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de LMAT | |
|---|---|
| Ingresos | US$256.28m |
| Coste de los ingresos | US$73.47m |
| Beneficio bruto | US$182.82m |
| Otros gastos | US$120.41m |
| Beneficios | US$62.40m |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 2.73 |
| Margen bruto | 71.33% |
| Margen de beneficio neto | 24.35% |
| Ratio deuda/patrimonio | 41.5% |
¿Cómo se ha desempeñado LMAT a largo plazo?
Ver rendimiento histórico y comparativaDividendos
1.1%
Rentabilidad actual por dividendo31%
Ratio de pagosAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/06/15 23:05 |
| Precio de las acciones al final del día | 2026/06/15 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
LeMaitre Vascular, Inc. está cubierta por 20 analistas. 9 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Michael Petusky | Barrington Research Associates, Inc. |
| Jan Wald | Benchmark Company |
| Raymond Myers | Benchmark Company |